论文部分内容阅读
目的探讨瑞舒伐他汀对急性冠脉综合征(ACS)患者血清内皮素(ET-1)、单核细胞趋化蛋白(MCP-1)和基质金属蛋白酶-9(MMP-9)的影响。方法 60例急性冠脉综合征患者随机分为瑞舒伐他汀组和常规治疗组(对照组)各30例。瑞舒伐他汀组在常规治疗基础上给予瑞舒伐他汀片10mg,1次/d,治疗6周。测定治疗前后血清ET-1、MCP-1和MMP-9水平并进行比较。结果两组治疗前ET-1、MCP-1和MMP-9水平无明显差异(P>0.05),瑞舒伐他汀组治疗后较对照组治疗后ET-1、MCP-1和MMP-9水平明显降低,差异有统计学意义(P<0.05)。结论瑞舒伐他汀能够降低血清ET-1、MCP-1和MMP-9水平,明显减轻炎症反应,改善血管内皮功能,稳定动脉粥样硬化斑块,在ACS的治疗中具有重要作用。
Objective To investigate the effect of rosuvastatin on serum endothelin (ET-1), monocyte chemotactic protein (MCP-1) and matrix metalloproteinase-9 (MMP-9) in patients with acute coronary syndrome (ACS) Methods Sixty patients with acute coronary syndrome were randomly divided into rosuvastatin group and control group, 30 cases in each group. Rosuvastatin group on the basis of conventional treatment given rosuvastatin tablets 10mg, 1 / d, for 6 weeks. Serum levels of ET-1, MCP-1 and MMP-9 were measured and compared before and after treatment. Results There was no significant difference in the levels of ET-1, MCP-1 and MMP-9 between the two groups before treatment (P> 0.05). After treatment with rosuvastatin, ET-1, MCP- Significantly lower, the difference was statistically significant (P <0.05). Conclusions Rosuvastatin can reduce the levels of ET-1, MCP-1 and MMP-9 in serum, reduce inflammation, improve endothelial function and stabilize atherosclerotic plaque. It plays an important role in the treatment of ACS.